Compare Cassava Sciences Inc (FLNA) vs Zillow Group Inc Class C (Z) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Zillow Group (Z) trades at $27.28, down 1.52% on the day, with technical indicators signaling a bearish trend amid weak moving averages. The company reported revenue of $2.58 billion in 2025, with net income turning positive at $23 million, and recent quarters show mixed earnings performance with two beats and one miss. Analyst sentiment is divided, with a consensus price target of $60.33, while news highlights focus on market competition and AI integration in real estate.

The stock faces headwinds from a challenging housing market and high valuation multiples, but long-term growth potential exists through its transaction platform expansion and AI initiatives. Risks include interest rate sensitivity and competitive pressures, yet institutional analyst coverage remains largely neutral to positive, suggesting cautious optimism for recovery if execution improves.